How Will the Diagnostic Company Business Model Evolve to Incorporate Pharmacogenomics?
An Interview with Stephen Little of DxS Ltd. Emerging pharmacogenomics technologies are presenting the drug discovery and development community with the promise of targeted therapies and potential new revenue streams. Pharmacogenomics is also creating new opportunities for diagnostic companies to develop tests that can be used to determine patient response to a drug and screen out inappropriate candidates. The keyand challengeto the widespread adoption of pharmacogenomic testing will be to successfully navigate the evolving regulatory requirements and commercial challenges to formulate business models that will enable diagnostic companies to forge mutually beneficial partnerships with drug companies. In this article, Stephen Little, Chief Executive Officer of DxS Ltd., discusses the market opportunities, challenges, and outlook for emerging pharmacogenomic tests and the possible business models for diagnostics companies to use their tests in combination with therapeutics. A complete an
Related Questions
- How do I register a business name in Ontario, incorporate a company, register a non-profit corporation or search for basic information about an Ontario registered company?
- How Will the Diagnostic Company Business Model Evolve to Incorporate Pharmacogenomics?
- What does it mean to incorporate a company?
